Telix Pharmaceuticals (TLX) Debt to Equity (2023 - 2024)

Telix Pharmaceuticals (TLX) has disclosed Debt to Equity for 2 consecutive years, with $1.0 as the latest value for Q4 2024.

  • Quarterly Debt to Equity rose 1530.78% to $1.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.0 through Dec 2024, up 1530.78% year-over-year, with the annual reading at $1.0 for FY2024, 1530.78% up from the prior year.
  • Debt to Equity for Q4 2024 was $1.0 at Telix Pharmaceuticals, up from $0.06 in the prior quarter.
  • The five-year high for Debt to Equity was $1.0 in Q4 2024, with the low at $0.06 in Q4 2023.